CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC) (CompARE)

  • participants needed
  • sponsor
    University of Birmingham
Updated on 5 February 2023
serum pregnancy test
squamous cell carcinoma
neutrophil count
renal function test
oropharyngeal cancer
international normalised ratio
oropharyngeal squamous cell carcinoma


CompARE is a multicentre, phase III open-label randomised controlled trial using an adaptive, Multi-Arm, Multi-Stage (MAMS) design.


The CompARE Trial examines alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer in an adult patient population. The aim is to assess whether escalated radiotherapy, adding surgery or immunotherapy will improve overall survival and quality of life in these patients.

Condition Oropharyngeal Cancer
Treatment cisplatin, Radiotherapy, durvalumab, Dose-escalated radiotherapy
Clinical Study IdentifierNCT04116047
SponsorUniversity of Birmingham
Last Modified on5 February 2023

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note